

Christopher M Hillis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3395341/publications.pdf>

Version: 2024-02-01

29
papers

229
citations

1307594

7
h-index

996975

15
g-index

29
all docs

29
docs citations

29
times ranked

402
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Adjudication of Adverse Events Following Rectal Cancer Surgery: Observational Case Series in a Region of Ontario, Canada. <i>Annals of Surgical Oncology</i> , 2022, 29, 1182-1191.	1.5	2
2	Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study. <i>Leukemia Research</i> , 2022, 113, 106788.	0.8	0
3	A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre. <i>Gynecologic Oncology</i> , 2021, 161, 236-243.	1.4	5
4	Response to Adverse cardiac outcomes in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors. <i>Heart</i> , 2021, 107, 1680.2-1681.	2.9	0
5	Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. <i>Current Oncology Reports</i> , 2021, 23, 113.	4.0	22
6	ASO Visual Abstract: Identification and Adjudication of Adverse Events following Rectal Cancer Surgery. Observational Case Series in a Region of Ontario, Canada. <i>Annals of Surgical Oncology</i> , 2021, 28, 672-673.	1.5	0
7	Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease. <i>Heart</i> , 2021, 107, 667-673.	2.9	13
8	Fitness Assessment of Elderly Patients with AML and Outcomes. <i>Blood</i> , 2021, 138, 3379-3379.	1.4	0
9	Devices to Reduce the Volume of Blood Taken for Laboratory Testing in ICU Patients: A Systematic Review. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1074-1079.	2.8	17
10	The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. <i>Leukemia Research</i> , 2020, 88, 106285.	0.8	0
11	Investigation and management of erythrocytosis. <i>Cmaj</i> , 2020, 192, E913-E918.	2.0	33
12	Increased Health Resource Utilization with the Introduction of Matrix for First-Line Treatment of Primary Central Nervous System Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
13	Engaging residents to choose wisely: Resident Doctors of Canada resource stewardship recommendations. <i>Canadian Medical Education Journal</i> , 2019, 10, e39-e55.	0.4	3
14	Impact of organizational interventions on reducing inappropriate intravenous immunoglobulin (IVIg) usage: A systematic review and meta-analysis. <i>Transfusion and Apheresis Science</i> , 2018, 57, 215-221.	1.0	7
15	Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practice. <i>Thrombosis Research</i> , 2018, 167, 6-8.	1.7	1
16	Hematologic Manifestations of Liver Disease. , 2018, , 2238-2243.		0
17	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2017, 160, 97-104.	1.7	18
18	A proposed solution to a urological tightrope walk: The challenge of transition of spina bifida patients from pediatric to adult care in Ontario. <i>Canadian Urological Association Journal</i> , 2016, 10, 306.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Appendix for: "A proposed solution to a urological tightrope walk: The challenge of transition of spina bifida patients from pediatric to adult care in Ontario". Canadian Urological Association Journal, 2016, 10, 340.	0.6	1
20	A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. BMC Hematology, 2016, 16, 17.	2.6	5
21	Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation. Cmaj, 2016, 188, 361-362.	2.0	2
22	Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leukemia and Lymphoma, 2016, 57, 1300-1310.	1.3	77
23	Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Blood, 2016, 128, 3821-3821.	1.4	0
24	Failure to Achieve Early Molecular Milestone within 3 Months Is Associated with Higher Risk of Relapse and Worse Survival after Allogeneic Hematopoietic Stem Cell Transplant for Chronic Myeloid Leukemia Patients, Especially after Tyrosine Kinase Inhibitor Failure. Blood, 2016, 128, 1907-1907.	1.4	0
25	Adherence to Chronic Myeloid Leukemia Monitoring and Treatment Guidelines in Canadian Registries. Blood, 2016, 128, 3079-3079.	1.4	1
26	The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments. Annals of Hematology, 2015, 94, 541-545.	1.8	17
27	Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis. Blood, 2015, 126, 4030-4030.	1.4	0
28	A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 4446-4446.	1.4	1
29	Assessing Disease Stability of Patients with Myelodysplastic Syndrome for an Age of Blood Randomized Controlled Trial: A Chart Review. Blood, 2015, 126, 5252-5252.	1.4	0